\uff5e Bristol Myers Squibb\u793e\u306fCelgene\u793e\u3068\u306e\u5408\u4f75\u306b\u3088\u308a\u3001\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u30b7\u30b9\u30c6\u30e0\u3092<\/p>\n
\u5358\u4e00\u30b7\u30b9\u30c6\u30e0\u306b\u7d71\u5408\u3055\u305b\u3001Vault CTMS\u3092\u8a18\u9332\u7684\u306a\u30b9\u30d4\u30fc\u30c9\u3067\u672c\u683c\u7a3c\u50cd<\/p>\n
\u30b7\u30b9\u30c6\u30e0\u306e\u6700\u65b0\u5316\u3067\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u3092\u30b9\u30ea\u30e0\u5316\u3057\u3001\u8fc5\u901f\u306b\u60a3\u8005\u69d8\u3078\u533b\u85ac\u54c1\u3092\u63d0\u4f9b\u3000\uff5e<\/p>\n
<\/p>\n
2022\u5e744\u670827\u65e5<\/p>\n
³Ô¹Ï±¬ÁÏ Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
³Ô¹Ï±¬ÁÏ Systems\u3010NYSE:VEEV\u3011\uff08\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : Sebastian Bather\u3001\u4ee5\u4e0b ³Ô¹Ï±¬ÁÏ\uff09\u306f\u3001Bristol Myers Squibb\u793e\u304c\u30a8\u30f3\u30c9\u30c4\u30fc\u30a8\u30f3\u30c9\u306a\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u3092\u63a8\u9032\u3059\u308b\u305f\u3081\u306b³Ô¹Ï±¬ÁÏ Vault CTMS<\/a><\/strong>\u3092\u30b0\u30ed\u30fc\u30d0\u30eb\u5168\u793e\u306b\u5c0e\u5165\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u65b0\u305f\u306b\u5c0e\u5165\u3055\u308c\u305fCTMS\u306f\u3001Celgene\u793e\u7531\u6765\u306eCTMS\u3068Bristol Myers Squibb\u793e\u7531\u6765\u306eCTMS\u306b\u4ee3\u308f\u308b\u30b7\u30b9\u30c6\u30e0\u3067\u3001³Ô¹Ï±¬ÁÏ\u306eeTMF\u304a\u3088\u3073Study Startup\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3068\u7dca\u5bc6\u306b\u7d71\u5408\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u5c0e\u5165\u671f\u9593\u306f\u7dcf\u8a08\u306720\u30ab\u6708\u672a\u6e80\u3067\u3057\u305f\u3002 (\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001³Ô¹Ï±¬ÁÏ\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n <\/p>\n Bristol Myers Squibb\u793e\u306f\u3001³Ô¹Ï±¬ÁÏ\u304c\u63d0\u4f9b\u3059\u308b\u696d\u754c\u6700\u5148\u7aef\u306e\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u304a\u3088\u3073\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3092\u5168\u793e\u306b\u5c55\u958b\u3057\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u8fc5\u901f\u5316\u3068\u52b9\u7387\u5316\u3092\u76ee\u7684\u3068\u3057\u305f\u30a2\u30b8\u30e3\u30a4\u30eb\u3067\u30b7\u30f3\u30d7\u30eb\u306a\u7d71\u5408\u5316\u3055\u308c\u305f\u81e8\u5e8a\u8a66\u9a13\u30d7\u30ed\u30bb\u30b9\u3092\u78ba\u7acb\u3057\u307e\u3057\u305f\u3002<\/p>\n Bristol Myers Squibb\u793e\u306e\u30c7\u30b8\u30bf\u30eb\u304a\u3088\u3073\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306e\u6700\u9ad8\u8cac\u4efb\u8005\u3067\u3042\u308bGreg Meyers\u6c0f\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c³Ô¹Ï±¬ÁÏ\u793e\u3068\u306eR&D\u5168\u822c\u306b\u308f\u305f\u308b\u9577\u5e74\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u3055\u3089\u306b\u62e1\u5927\u3055\u305b\u308b\u3053\u3068\u306b\u306a\u308a\u3001\u5927\u3044\u306b\u671f\u5f85\u3057\u3066\u3044\u307e\u3059\u3002\u9867\u5ba2\u306e\u6210\u529f\u3068\u88fd\u54c1\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u306b\u5bfe\u3059\u308b³Ô¹Ï±¬ÁÏ\u306e\u7d99\u7d9a\u7684\u306a\u53d6\u7d44\u307f\u306f\u3001\u533b\u85ac\u54c1\u306e\u958b\u767a\u3068\u60a3\u8005\u69d8\u3078\u306e\u63d0\u4f9b\u3092\u30b0\u30ed\u30fc\u30d0\u30eb\u306b\u52a0\u901f\u3067\u304d\u308b\u3088\u3046\u652f\u63f4\u3057\u3066\u304f\u308c\u3066\u3044\u307e\u3059\u3002\u300d<\/p>\n ³Ô¹Ï±¬ÁÏ\u306eCEO\u3001Peter Gassner\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cBristol Myers Squibb\u793e\u306f\u5f0a\u793e\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u306e\u4e2d\u3067\u3082\u6307\u6298\u308a\u306e\u30a2\u30b8\u30e3\u30a4\u30eb\u3067\u5148\u9032\u7684\u306a\u4f01\u696d\u3067\u3059\u3002Celgene\u793e\u3068\u306e\u5408\u4f75\u306f\u88fd\u85ac\u696d\u754c\u53f2\u4e0a\u3067\u6700\u5927\u306eIT\u7d71\u5408\u30d7\u30ed\u30b8\u30a7\u30af\u30c8\u3067\u3057\u305f\u304c\u3001\u5358\u4e00\u306eCTMS\u306e\u5c0e\u5165\u309220\u30ab\u6708\u3067\u5b8c\u4e86\u3057\u305f\u3053\u3068\u306f\u307e\u3055\u306b\u753b\u671f\u7684\u3067\u3059\u3002\u3053\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3092\u5354\u529b\u3057\u3066\u9054\u6210\u3067\u304d\u305f\u3053\u3068\u3092\u5927\u5909\u3046\u308c\u3057\u304f\u601d\u3044\u307e\u3059\u3002\u300d<\/p>\n ³Ô¹Ï±¬ÁÏ Vault CTMS\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u306eHenry Galio\u306f\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c³Ô¹Ï±¬ÁÏ Vault CTMS\u306f\u5148\u9032\u7684\u306a\u6a5f\u80fd\u306b\u3088\u308a\u3001\u898f\u6a21\u306e\u5927\u5c0f\u3092\u554f\u308f\u305a\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u65bd\u3092\u7c21\u7d20\u5316\u3057\u307e\u3059\u3002\u4eca\u56de\u306e\u304d\u308f\u3081\u3066\u91cd\u8981\u3067\u8907\u96d1\u306aCTMS\u5c0e\u5165\u306b\u3042\u305f\u308a\u3001\u3059\u3070\u3089\u3057\u3044\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u767a\u63ee\u3057\u3066\u304f\u3060\u3055\u3063\u305fBristol Myers Squibb\u793e\u306e\u30c1\u30fc\u30e0\u306b\u611f\u8b1d\u7533\u3057\u4e0a\u3052\u307e\u3059\u3002\u300d<\/p>\n <\/p>\n \u3010<\/strong>³Ô¹Ï±¬ÁÏ Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u3010Forward-looking Statements<\/strong>\u3011<\/strong> Bristol Myers Squibb\u793e\u306fCelgene\u793e\u3068\u306e\u5408\u4f75\u306b\u3088\u308a\u3001\u81e8\u5e8a\u8a66\u9a13\u7ba1\u7406\u30b7\u30b9\u30c6\u30e0\u3092\u5358\u4e00\u30b7\u30b9\u30c6\u30e0\u306b\u7d71\u5408\u3055\u305b\u3001Vault CTMS\u3092\u8a18\u9332\u7684\u306a\u30b9\u30d4\u30fc\u30c9\u3067\u672c\u683c\u7a3c\u50cd<\/p>\n","protected":false},"author":131,"featured_media":47089,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-47082","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47082"}],"collection":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=47082"}],"version-history":[{"count":6,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47082\/revisions"}],"predecessor-version":[{"id":47154,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/47082\/revisions\/47154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media\/47089"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=47082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=47082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=47082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n³Ô¹Ï±¬ÁÏ Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u30671,100\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u3001\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002\u30d1\u30d6\u30ea\u30c3\u30af\u30fb\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30fb\u30b3\u30fc\u30dd\u30ec\u30fc\u30b7\u30e7\u30f3\u4f01\u696d\u3068\u3057\u3066³Ô¹Ï±¬ÁÏ\u306f\u3001\u9867\u5ba2\u3084\u5f93\u696d\u54e1\u3001\u63d0\u643a\u4f01\u696d\u3001\u682a\u4e3b\u3001\u30b5\u30fc\u30d3\u30b9\u63d0\u4f9b\u696d\u754c\u3092\u542b\u3080\u3059\u3079\u3066\u306e\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u306e\u5229\u76ca\u30d0\u30e9\u30f3\u30b9\u3092\u4fdd\u3064\u3053\u3068\u306b\u30b3\u30df\u30c3\u30c8\u3057\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001veeva.com\/jp<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. Such statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the period ended January 31, 2022, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 13 and 14), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"